Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0X4SI
|
||||
| Former ID |
DPR000102
|
||||
| Drug Name |
RS-504393
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Roche
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C25H27N3O3
|
||||
| InChI |
InChI=1S/C25H27N3O3/c1-17-8-9-22-20(16-17)25(31-24(29)27-22)11-14-28(15-12-25)13-10-21-18(2)30-23(26-21)19-6-4-3-5-7-19/h3-9,16H,10-15H2,1-2H3,(H,27,29)
|
||||
| InChIKey |
ODNICNWASXKNNQ-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 300816-15-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
14929247, 24696404, 46050378, 50112894, 79972630, 85788710, 103366079, 104024068, 134339542, 135566646, 135650944, 135698770, 136367799, 138230843, 151981512, 152258709, 152344313, 160647545, 160821210, 162023521, 162301649, 162832691, 163374671, 164023446, 172912668, 185964418, 204382744, 208265223, 223384980, 223573234, 235319579, 242059981, 249583053, 249826996, 250208962, 252059307, 252126288, 252156578, 252216233, 252436124
|
||||
| Target and Pathway | |||||
| Target(s) | C-C chemokine receptor type 2 | Target Info | Antagonist | [536223], [536550] | |
| C-C motif chemokine 2 | Target Info | Inhibitor | [536223], [536549] | ||
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| Chemokine signaling pathwayhsa04060:Cytokine-cytokine receptor interaction | |||||
| Chemokine signaling pathway | |||||
| NOD-like receptor signaling pathway | |||||
| TNF signaling pathway | |||||
| Chagas disease (American trypanosomiasis) | |||||
| Malaria | |||||
| Influenza A | |||||
| Herpes simplex infection | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| IL2 Signaling Pathway | |||||
| TGF_beta_Receptor Signaling Pathway | |||||
| Leptin Signaling Pathway | |||||
| RANKL Signaling PathwayNetPath_20:IL9 Signaling Pathway | |||||
| IL5 Signaling Pathway | |||||
| IL1 Signaling Pathway | |||||
| TSH Signaling Pathway | |||||
| TWEAK Signaling Pathway | |||||
| IL4 Signaling Pathway | |||||
| TNFalpha Signaling Pathway | |||||
| TSLP Signaling Pathway | |||||
| RANKL Signaling Pathway | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Defensins | |||||
| Spinal Cord Injury | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP2865:IL1 and megakaryotyces in obesity | |||||
| Activation of Genes by ATF4 | |||||
| Oncostatin M Signaling Pathway | |||||
| TNF alpha Signaling Pathway | |||||
| TWEAK Signaling Pathway | |||||
| IL-1 signaling pathway | |||||
| Folate Metabolism | |||||
| Vitamin B12 Metabolism | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| Ref 536223 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. | ||||
| Ref 542757 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 781). | ||||
| Ref 536223 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. | ||||
| Ref 536549 | Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19. | ||||
| Ref 536550 | Beneficial or detrimental effects of carotenoids contained in food: cell culture models. Mini Rev Med Chem. 2007 Nov;7(11):1120-8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.